Athersys, Inc. – NASDAQ:ATHX
Founder-led company
Athersys stock price today
$0.026
+0.01
+92.59%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 2 hours
Athersys stock price monthly change
-41.91%
month
Athersys stock price quarterly change
-95.37%
quarter
Athersys stock price yearly change
-98.29%
year
Athersys key metrics
Market Cap | N/A |
Enterprise value | 6.19M |
P/E | -0.15 |
EV/Sales | 1.17 |
EV/EBITDA | 0.85 |
Price/Sales | 2.08 |
Price/Book | -0.66 |
PEG ratio | N/A |
EPS | -2.01 |
Revenue | N/A |
EBITDA | -40.69M |
Income | -37.38M |
Revenue Q/Q | -100% |
Revenue Y/Y | -98.65% |
Profit margin | -1125.62% |
Oper. margin | -1607.58% |
Gross margin | 43.79% |
EBIT margin | -1607.58% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAthersys stock price history
Athersys stock forecast
Athersys financial statements
| Dec 2022 | 32K | -12.40M | -38762.5% |
|---|---|---|---|
| Mar 2023 | 0 | -8.28M | |
| Jun 2023 | 49K | -12.92M | -26375.51% |
| Sep 2023 | 0 | -3.77M |
| 2025 | 21.3M | -8.36M | -39.26% |
|---|
Analysts Price target
Financials & Ratios estimates
| Dec 2022 | 27731000 | 51.58M | 186.01% |
|---|---|---|---|
| Mar 2023 | 21632000 | 52.64M | 243.36% |
| Jun 2023 | 10477000 | 47.89M | 457.15% |
| Sep 2023 | 7428000 | 43.82M | 589.97% |
| Dec 2022 | -11.96M | 1.74M | 5.47M |
|---|---|---|---|
| Mar 2023 | -5.96M | 105K | -56K |
| Jun 2023 | -4.58M | 0 | 3.26M |
| Sep 2023 | -3.84M | 122K | 2.94M |
Athersys alternative data
| Aug 2023 | 24 |
|---|---|
| Sep 2023 | 24 |
| Oct 2023 | 24 |
| Nov 2023 | 24 |
| Dec 2023 | 24 |
| Jan 2024 | 24 |
| Feb 2024 | 24 |
| Mar 2024 | 24 |
| Apr 2024 | 24 |
| May 2024 | 24 |
| Jun 2024 | 24 |
| Jul 2024 | 24 |
Athersys other data
12.97%
-4.19%
of ATHX is owned by hedge funds
25
-81
1.34M
-329.25K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Mar 2022 | 132800 | 0 |
| Nov 2022 | 100000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | CAMARDO DANIEL A. director, officer: CEO | Common Stock | 100,000 | $0.55 | $55,000 | ||
Purchase | CAMARDO DANIEL A. director, officer: CEO | Common Stock | 132,800 | $0.77 | $102,256 | ||
Option | LEHMANN WILLIAM JR officer: Interim .. | Stock Option (right to purchase) | 5,000 | $1.28 | $6,400 | ||
Option | LEHMANN WILLIAM JR officer: Interim .. | Common Stock | 5,000 | $1.28 | $6,400 | ||
Purchase | KOLA ISMAIL director | Common Stock | 85,000 | $0.96 | $81,685 | ||
Purchase | MACLEOD IVOR officer: Chief Financial Officer | Common Stock | 15,000 | $1.18 | $17,700 | ||
Option | LEHMANN WILLIAM JR officer: Interim .. | Stock Option (right to purchase) | 5,000 | $1.28 | $6,400 | ||
Option | LEHMANN WILLIAM JR officer: Interim .. | Common Stock | 5,000 | $1.28 | $6,400 | ||
Sale | LEHMANN WILLIAM JR officer: Interim .. | Common Stock | 30,000 | $1.41 | $42,300 | ||
Sale | HARRINGTON JOHN J director, officer.. | Common Stock | 11,981 | $1.47 | $17,612 |
| Quarter | Transcript |
|---|---|
| Q3 2022 15 Nov 2022 | Q3 2022 Earnings Call Transcript |
| Q2 2022 11 Aug 2022 | Q2 2022 Earnings Call Transcript |
| Q4 2021 15 Mar 2022 | Q4 2021 Earnings Call Transcript |
| Q3 2021 15 Nov 2021 | Q3 2021 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Ivor Macleod CPA, M.B.A. (1962) Chief Financial Officer & Principal Accounting Officer | $587,210 |
| Dr. John J. Harrington (1967) Co-Founder, Chief Scientific Officer, Executive Vice President & Director | $534,860 |
| Mr. William B. J. Lehmann Jr., M.B.A., J.D., MBA (1966) Pres, Chief Operating Officer, Sec. & Interim Chief Executive Officer | $533,600 |
Athersys: Focus On Stroke
Athersys - Hero Or Zero Opportunity
Athersys: Near-Term Progress In Stem Cell Phase 3 Trials Could Multiply Shares In 2022
Athersys: COVID-ARDS Is The Company's Most Important Target
Athersys Shares Are Ready To Rumble Following Period Of Turmoil
Athersys: Stem Cell Opportunity For Risk-Tolerant Investors - Q1 2021 Update
-
What's the price of Athersys stock today?
One share of Athersys stock can currently be purchased for approximately $0.03.
-
When is Athersys's next earnings date?
Unfortunately, Athersys's (ATHX) next earnings date is currently unknown.
-
Does Athersys pay dividends?
No, Athersys does not pay dividends.
-
What is Athersys's stock symbol?
Athersys, Inc. is traded on the NASDAQ under the ticker symbol "ATHX".
-
What is Athersys's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Athersys?
Shares of Athersys can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Athersys's key executives?
Athersys's management team includes the following people:
- Mr. Ivor Macleod CPA, M.B.A. Chief Financial Officer & Principal Accounting Officer(age: 63, pay: $587,210)
- Dr. John J. Harrington Co-Founder, Chief Scientific Officer, Executive Vice President & Director(age: 58, pay: $534,860)
- Mr. William B. J. Lehmann Jr., M.B.A., J.D., MBA Pres, Chief Operating Officer, Sec. & Interim Chief Executive Officer(age: 59, pay: $533,600)
-
Is Athersys founder-led company?
Yes, Athersys is a company led by its founder Dr. John J. Harrington.
-
How many employees does Athersys have?
As Jul 2024, Athersys employs 24 workers.
-
When Athersys went public?
Athersys, Inc. is publicly traded company for more then 18 years since IPO on 12 Jun 2007.
-
What is Athersys's official website?
The official website for Athersys is athersys.com.
-
Where are Athersys's headquarters?
Athersys is headquartered at 3201 Carnegie Avenue, Cleveland, OH.
-
How can i contact Athersys?
Athersys's mailing address is 3201 Carnegie Avenue, Cleveland, OH and company can be reached via phone at +216 4319900.
Athersys company profile:
Athersys, Inc.
athersys.comExchange:
NASDAQ
Full time employees:
24
Industry:
Biotechnology
Sector:
Healthcare
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.
3201 Carnegie Avenue
Cleveland, OH 44115-2634
Cleveland, OH 44115-2634
CIK: 0001368148
ISIN: US04744L2051
CUSIP: 04744L106
